Eyevensys announced the expansion of its leadership team with the appointment of Gerald Cagle, PhD, as the Board’s Chairman, Francine Behar-Cohen as Chief Innovation Officer, and Thierry Bordet as the Chief Scientific Officer.
Dr. Cagle, who joined Eyevensys’ Board of Directors in 2018, was the former Senior Vice President and Chief Scientific Officer at Alcon Laboratories. He will replace Garth Cumberlidge, PhD, the company’s current Chairman. Dr. Cagle will work closely with and advise Dr. Patricia Zilliox, Eyevensys’ CEO, in strategic decision making for the company. Dr. Cagle said, “I am looking forward to working even closer with the Eyevensys management team to help it achieve its next level of growth and I am truly honored to lead such an extraordinary Board as its Chairman.”
Eyevensys founder and previous Chief Scientific Officer, Prof. Behar-Cohen will assume the role of Chief Innovation Officer, a newly created position at the company. “Within the next 10 years, gene therapies will be accepted treatments for both rare genetic retinal conditions and more common eye diseases and patients will be able to have treatments based on their own specific genetic profiles. Eyevensys is at the forefront of creating technologies that will be best-in-class to treat and prophylactically prevent future ocular maladies,” Pr. Behar-Cohen said in a company news release.
Dr. Thierry Bordet has been promoted to Chief Scientific Officer, from his previous position as preclinical director for the company. Prior to coming to Eyevensys in 2017, Dr. Bordet had over 15 years of experience in the biotechnology sector having managed drug development programs for small molecules, gene therapies, cell-based therapies and tissue engineered products. He was most recently preclinical development director at the Biotherapies Institute for Rare Diseases, in Evry, France, where he designed development strategies for advanced therapy medicinal products for various indications, including inherited retinitis pigmentosa.